| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $5,685,126 | 7 | 100 |
Sells | $0 | 0 | 0 |
| BROADWOOD PARTNERS, L.P. | 10 percent owner | 7 | $5.69M | 0 | $0 | $5.69M |
Insight Molecular Diagnostics Inc. functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, Insight Molecular Diagnostics provides a range of …
Over the last 12 months, insiders at Insight Molecular Diagnostics Inc. have bought $5.69M and sold $0 worth of Insight Molecular Diagnostics Inc. stock.
On average, over the past 5 years, insiders at Insight Molecular Diagnostics Inc. have bought $12.79M and sold $125,061 worth of stock each year.
Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. (10 percent owner) — $5.69M.
The last purchase of 250,923 shares for transaction amount of $913,134 was made by BROADWOOD PARTNERS, L.P. (10 percent owner) on 2026‑04‑27.
| 2026-04-27 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 250,923 0.9048% | $3.64 | $913,134 | +18.23% | ||
| 2026-04-24 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 38,880 0.1358% | $3.53 | $137,083 | +19.68% | ||
| 2026-04-23 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 280,381 1.0394% | $3.50 | $982,034 | +27.27% | ||
| 2026-04-20 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 40,690 0.1533% | $3.88 | $157,967 | +11.28% | ||
| 2026-04-17 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 40,114 0.139% | $3.57 | $143,251 | +15.49% | ||
| 2026-04-16 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 102,057 0.3733% | $3.45 | $351,658 | +26.21% | ||
| 2026-02-10 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 521,739 1.4124% | $5.75 | $3M | -39.95% | ||
| 2025-02-07 | SMITH PATRICK W | 10 percent owner | 1.08M 1.0324% | $2.05 | $2.21M | +61.19% | ||
| 2025-02-07 | James Andrea S. | Chief Financial Officer | 97,561 0.0935% | $2.05 | $200,000 | +61.19% | ||
| 2025-02-06 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 5.17M 4.9489% | $2.05 | $10.59M | +57.56% | ||
| 2025-02-04 | SMITH PATRICK W | 10 percent owner | 25 <0.0001% | $2.02 | $51 | +51.17% | ||
| 2025-01-31 | SMITH PATRICK W | 10 percent owner | 890 0.0008% | $2.01 | $1,789 | +54.59% | ||
| 2025-01-30 | SMITH PATRICK W | 10 percent owner | 318 0.0003% | $2.01 | $639 | +59.20% | ||
| 2025-01-29 | SMITH PATRICK W | 10 percent owner | 3,880 0.0036% | $2.01 | $7,799 | +57.92% | ||
| 2025-01-14 | SMITH PATRICK W | 10 percent owner | 10,386 0.0104% | $2.15 | $22,323 | +42.79% | ||
| 2025-01-13 | SMITH PATRICK W | 10 percent owner | 5,669 0.0055% | $2.08 | $11,792 | +47.60% | ||
| 2024-12-26 | SMITH PATRICK W | 10 percent owner | 90,219 0.0898% | $2.13 | $192,166 | +41.08% | ||
| 2024-12-26 | Arno Andrew | director | 12,500 0.0123% | $2.11 | $26,350 | +41.08% | ||
| 2024-12-05 | James Andrea S. | Chief Financial Officer | 20,000 0.0214% | $2.29 | $45,800 | +26.96% | ||
| 2024-10-02 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 1.32M 1.8121% | $2.95 | $3.88M | -6.89% |
| BROADWOOD PARTNERS, L.P. | 10 percent owner | 12684884 38.7629% | $34.76M | 21 | 0 | <0.0001% |
| BROADWOOD CAPITAL INC | 23353697 71.365% | $63.99M | 1 | 0 | <0.0001% | |
| Kamen Efrem | 8520146 26.0362% | $23.35M | 1 | 1 | <0.0001% | |
| PURA VIDA INVESTMENTS, LLC | 10 percent owner | 8090202 24.7223% | $22.17M | 2 | 1 | <0.0001% |
| SMITH PATRICK W | 10 percent owner | 2872671 8.7784% | $7.87M | 8 | 0 | +51.94% |
| KINGSLEY ALFRED D | director | 469111 1.4335% | $1.29M | 3 | 3 | <0.0001% |
| ANDREWS RONALD ASBURY | President & CEO | 333212 1.0182% | $913,000.88 | 8 | 0 | +3.75% |
| James Andrea S. | Chief Financial Officer | 151231 0.4621% | $414,372.94 | 3 | 0 | +27.09% |
| Redmond Cavan M. | 110863 0.3388% | $303,764.62 | 2 | 0 | <0.0001% | |
| Levine Mitchell S | Chief Financial Officer | 87080 0.2661% | $238,599.20 | 5 | 0 | +111.03% |
| Arno Andrew | director | 81554 0.2492% | $223,457.96 | 7 | 0 | <0.0001% |
| Gutfreund John Peter | director | 75000 0.2292% | $205,500.00 | 2 | 0 | <0.0001% |
| Last Andrew J. | 70170 0.2144% | $192,265.80 | 2 | 0 | <0.0001% | |
| Carter Jennifer L. | 30500 0.0932% | $83,570.00 | 1 | 0 | <0.0001% | |
| GRIFFITH MELINDA | 30000 0.0917% | $82,200.00 | 1 | 0 | <0.0001% | |
| Ross Douglas T. | Chief Scientific Officer | 20317 0.0621% | $55,668.58 | 1 | 0 | <0.0001% |
| Paulsen Gisela | Chief Operating Officer | 16500 0.0504% | $45,210.00 | 1 | 0 | <0.0001% |
| KALAJIAN TONY T | Sr.VP/Chief Accounting Officer | 15000 0.0458% | $41,100.00 | 2 | 0 | +163.52% |
| Parker Albert P | Chief Operating Officer | 5000 0.0153% | $13,700.00 | 1 | 0 | +163.52% |
| ANNETT WILLIAM | President and CEO | 3500 0.0107% | $9,590.00 | 1 | 0 | |
| Riggs Josh | CEO and President | 3505 0.0107% | $9,603.70 | 1 | 0 | <0.0001% |
| HESTERBERG LYNDAL K. | Sr VP, Research & Development | 874 0.0027% | $2,394.76 | 1 | 0 |
| Increased Positions | 17 | +58.62% | 438,416 | +2.69% |
| Decreased Positions | 9 | -31.03% | 86,190 | -0.53% |
| New Positions | 9 | New | 283,676 | New |
| Sold Out Positions | 2 | Sold Out | 16,503 | Sold Out |
| Total Postitions | 37 | +27.59% | 17M | +2.16% |